UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 12, 2020

APOLLO MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation)

001-37392 (Commission File Number)

95-4472349 (I.R.S. Employer Identification Number)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801 (Address of principal executive offices) (zip code)

(626) 282-0288

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	AMEH	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Apollo Medical Holdings, Inc. (the "Company") is scheduled to present at the Credit Suisse 29th Virtual Annual Healthcare Conference on November 12, 2020. A copy of certain information to be presented by the Company's officers at the conference is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information contained in this Current Report on Form 8-K, including the exhibit referenced herein, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
00.1	
99.1	Certain Information Presented at Credit Suisse 29th Virtual Annual Healthcare Conference on November 12, 2020

Forward-Looking Statements

This current report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include words such as "forecast," "guidance," "projects," "estimates," "anticipates," "believes," "expects," "intends," "may," "plans," "seeks," "should," or "will," or the negative of these words or similar words. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in each such statement. A number of important factors could cause actual results to differ materially from those included within or contemplated by the forward-looking statements, including, but not limited to, the factors described in our filings with the Securities and Exchange Commission, including the Company's most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q. The Company does not undertake any responsibility to update any of these factors or to announce publicly any revisions to any of the forward-looking statements contained in this or any other document, whether as a result of new information, future events, or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 12, 2020

APOLLO MEDICAL HOLDINGS, INC.

 By:
 /s/ Thomas S. Lam, M.D.

 Name:
 Thomas S. Lam, M.D.

 Title:
 Co-Chief Executive Officer and President



Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, integration of acquired companies and any projections of earnings, revenue, EBITDA, Adjusted EBITDA or other financial items, such as the Company's projected capitation and future liquidity, and may be identified by the use of forward-looking terms such as "anticipate," "could," "can," "may," "might," "potential," "predict," "should, "estimate," "expect," "project," "believe," "plan," "envision," "intend," "continue," "target," "seek," "will," "would," and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward-looking statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors discussed in the Company's Annual Report on Form 10-K filed with the SEC on March 16, 2020 and subsequent Quarterly Reports on Form 10-Q.


Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or implied in any forwardlooking statements, you should not place undue reliance on any such forward-looking statements. Any forward-looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertake any obligation to update any forward-looking statement, as a result of new information, future events or otherwise.


apollomed

www.apollomed.net

Company Overview


Apollo Medical Holdings, Inc. ("ApolloMed") is a leading physician-centric, technology-enabled, risk-bearing, healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner.






Where ApolloMed Fits in the U.S. Healthcare Ecosystem

Through its MSO, consolidated IPAs, and ACO, ApolloMed is one of the nation's largest population health management companies and one of few that provides **full spectrum of care**.



Our Service Offerings & Revenue Model

Across all aspects of care delivery, our offerings provide a steady revenue stream.



Organizational Overview

Together with our affiliated physician groups and consolidated entities, ApolloMed manages the medical lives of approximately 1.1 million members.



How ApolloMed Provides Value-Based Care

We created a technology-enabled platform to deliver value-based care through our horizontally and vertically integrated physician-centric model.

Traditional Fee-for-Service Model	ApolloMed's Value-Based Care Model
Siloed care with little coordination among providers	Integrated healthcare ecosystem
olume-based system results in redundant, contradictory care	Reduce redundant and/or unnecessary testing
Limited integration and data sharing	Actionable data allows providers to make informed decisions
Reactive care	Emphasize preventative/chronic care management
Little sensitivity to cost	Incentive to deliver better care at lower cost
Poor patient experience	Improved patient experience and outcomes
www.apol	lomed.net 8

Our Value-Based Care Model Benefits all Stakeholders

PATIENTS

- · Improved health outcomes
- · Improved patient experience
- · Reduced out-of-pocket expenses for patients

PROVIDERS

- Reduced burn-out with flexible schedules and greater work-life balance
- · Relief of administrative burden
- · Customized technology-enabled clinical support
- · Compensation driven by quality

() apollomed


PAYORS

- · Improved population health and higher quality scoring
- · Increased membership
- Significant savings (capitation arrangements align financial incentives with proactive and preventative healthcare)

PARTNERS

- · Increased utilization of facilities
- Focuses care in the most cost-effective setting while enabling ApolloMed and hospital partners to share in risk pool dollars

www.apollomed.net



Select ApolloMed Points of Care



() apollomed

www.apollomed.net

Why Physicians Partner with ApolloMed

ApolloMed empowers its physicians to cost-effectively deliver the highest quality of care to its patients by aligning financial incentives around proactive and preventative healthcare.




Long-Term Relationships with a Diversified Payor Mix




Proprietary Technology Platform

ApolloMed combines technology and data analytics, powered by machine learning and artificial intelligence, with clinical expertise.




Proprietary Technology Platform

Our solutions address three key pain points in managed healthcare delivery:





A Significant Market Opportunity in Provider Services



Industry Peers






Ticker	NASDAQ: AMEH	NYSE: OSH	NASDAQ: ONEM	NYSE: EVH
Business	A leading physician-centric, technology-enabled, risk-bearing healthcare management company	A network of value-based, primary care centers for adults on Medicare	A membership-based and technology- powered primary care platform with seamless digital health and inviting in- office care	A health care company that delivers proven clinical and administrative solutions to payers and providers
# of Members Served	1.1M	89,500	511,000	3.5M
Market Cap	\$653M	\$12.4B	\$4.0B	\$1.0B
TTM Revenue	\$689M	\$729M	\$303.8M	\$942.6M
EV/Revenue	1.2 ⁽³⁾	17.5	12.1	1.3
TTM EBITDA	\$180.7M ⁽¹⁾⁽²⁾	(\$103.5M)	(\$67.1M)	(\$458.2M)
EV/EBITDA	4.4(3)	(123.3)	(54.8)	(2.8)

() apollomed

("Bright"), which closed on April 30, 2020, UCAP is a 100% owned subsidiary of Allied Physicians of California, a Professional Corporation ("APC"), UCAP's 48,9% investment in UCI is an excluded asset that remains solely for the benefit of APC and its shareholders. As such, the gain on sale does not affect the net income and adjusted EBITDA attributable to ApolloMed. (18 See "Current Capitalization" side for more information.

ApolloMed is Executing Clear Growth Strategy



Enter new markets and geographies, expand outreach through current ACO program presence in 15 states

Continue to invest in technology, preventative care and automation to further drive clinical care capabilities and margin expansion

Expand physician network and membership

Establish new and deepen existing partnerships

() apollomed

www.apollomed.net


Integration of Acquired IPAs

ApolloMed continues to implement processes to fully integrate the IPAs acquired in 2019 into its framework with expected completion within 3 years of closing.



Expanding Nationwide

ApolloMed is well positioned to increase our existing presence in California while exploring opportunities to expand our geographic footprint beyond the state.



Our Response to COVID-19

ApolloMed has implemented measures to support our members, physicians and employees during the ongoing COVID-19 pandemic.



- Drive-thru testing stations
- Increased testing capabilities
- Immediate access
- Telehealth options



- Access to critical supplies
- Reduced patient loads
- · Relief of administrative burdens
- Knowledge sharing



- · Flexible work arrangements
- Digital workspaces
- Priority telehealth access

Prioritizing the health and safety of our community

D apollomed

www.apollomed.net

Investment Summary

Large and rapidly growing market opportunity focused on value-based care	A value-based care model supported by proprietary care management technologies	A compelling financial model with predictable unit economics and potential upside from risk-sharing
Multifaceted growth strategy driven by the shift to value- based care	Combination of innovative technologies and clinical expertise for operational excellence and efficiencies (margin expansion)	Clinically experienced management team committed to enhancing shareholder value


S apollomed


www.apollomed.net




Historical Financial Profile








Historical Net Income Attributable to ApolloMed Growth




2020 Guidance

\$ in millions	Q3 2020 YTD Results	2020 Guidance Range		
Total Revenue	\$510.4	\$665.0-\$675.0		
Net Income	\$109.4 (1)	\$110.0-\$120.0		
EBITDA ⁽²⁾	\$173.1 ⁽¹⁾	\$182.0-\$194.0		
Adjusted EBITDA ⁽²⁾	\$90.8	\$97.0-\$112.0		
	(2) See "Reconciliation o Non-GAAP Financial assurance that actua	come includes pre-tax gain on sale of UCI of \$99.6M. If Net Income to EBITDA and Adjusted EBITDA" and "Use of Measures" below for more information. There can be no I amounts will not be materially higher or lower than these orward-Looking Statements" above.		
apollomed	www.apollomed.net			

Quarterly Performance



Revenue Breakdown



Balance Sheet Highlights

\$ in millions	9/30/2020	12/31/2019	\$ Change	% Change
Cash and cash equivalents and investments in marketable securities	\$284.4	\$219.7	\$64.7	29.4%
Working capital	\$235.2	\$223.6	\$11.6	\$5.2%
Total stockholders' equity	\$229.4	\$192.3	\$37.1	19.2%

() apollomed

www.apollomed.net

Current Capitalization

Share Price (as of 11/5/2020) Common Shares Outstanding	17.75 36.8
Market Capitalization	\$ 653.2
Plus: Total Bank Debt	240.5
Less: Cash and Cash Equivalents (1)	(99.0
Implied Enterprise Value	\$ 794.7

Note: See appendix for EBITDA reconciliation. Balance sheet data as of 9/30/2020. (1) Excludes restricted cash of \$67mm.

() apollomed

www.apollomed.net



Management – A Team of Industry Veterans



Apollomed

www.apollomed.net

U.S. Value-Based Landscape – Providers

The value-based care landscape continues to broaden as more companies enter the market to take capitation risk directly or assist physicians in the transition to risk-based arrangements.



Reconciliation of Net Income to EBITDA and Adjusted EBITDA

(\$ in millions)

	Three	Months End	ed Septe	mber 30,	Nine Months Ended September 30,									
		2020		2019	2020		2019							
Netincome	\$	25.4	\$	10.7	\$	109.4	\$	19.0						
Depreciation and amortization		4.7		4.9		14.0		13.8						
Provision for income taxes		10.8		3.7 0.8		44.2 8.0		6.5 1.3						
Interest expense Interest income		2.5												
						(0.8)		(0.5)		(2.5)		(1.3		
EBITDA	\$	42.6	\$	19.6	\$	173.1	\$	39.						
Income from equity method investments	\$	(0.4)	\$	(2.1)	\$	(3.3)	\$	(1.						
Gain on sale of equity method investment				-		(99.7)								
Other income								(0.1)		(2.6)		(1.5)		(2.)
Provider bonus payments		6.5		2.1		8.5		12.						
Impairment of intangibles				2.0				2.						
Provision for doubtful accounts		-		-		-		(1.4						
Net loss adjustment for recently acquired IPAs		4.8		3.7		13.7		5.						
Adjusted EBITDA	\$	53.4	\$	22.7	\$	90.8	\$	53.						

() apollomed

www.apollomed.net

TTM EBITDA Reconciliation

(\$ in millions)				Three Mor	the End	had				
	December 31, 2019		March 31, 2020		June 30, 2020		September 30, 2020		TTM 2020	
Net (loss) income	\$	(1.3)	\$	3.0	\$	81.0	\$	25.4	\$	108.1
Depreciation and amortization		4.5		4.7		4.6		4.7		18.5
Provision for income taxes		1.7		1.6		31.9		10.8		46.0
Interest expense		3.4		2.9		2.7		2.5		11.5
Interest income		(0.7)		(1.0)		(0.9)		(0.8)		(3.4)
EBITDA	\$	7.6	\$	11.2	\$	119.3	\$	42.6	\$	180.7
Loss (income) from equity method investments	\$	8.0	\$	(2.1)	\$	(0.8)	\$	(0.4)	s	4.7
Gain on sale of equity method investment		-		-		(99.7)				(99.7
Other (income) expense		(0.2)		(0.1)		(1.3)		(0.1)		(1.7)
Provider bonus payments						2.0		6.5		8.5
Impairment of intangibles										
Provision for doubtful accounts		-						-		-
Net loss adjustment for recently acquired IPAs		5.5		4.8		4.1		4.8		19.2
Adjusted EBITDA	Ś	20.9	ŝ	13.8	Ś	23.6	Ś	53.4	Ś	111.7

() apollomed

www.apollomed.net

Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA

(\$	in	millions)	

	Yea	ember 31, 2020 High		
Net income (1)	s	110.0	s	120.0
Depreciation and amortization		19.0		20.0
Provision for income taxes Interest expense		46.0		47.0 11.0
		10.0		
Interest income		(3.0)		(4.0)
EBITDA	\$	182.0	\$	194.0
Income from equity method investments (2)	\$	(100.0)	\$	(99.0
Net loss adjustment for recently acquired IPAs		15.0		17.0
Adjusted EBITDA	\$	97.0	\$	112.0

^{D1}Net income and earnings before income tax, depreciation and amortization ("EBITDA") include the gain on sale of UCAP's 48.9% investment in UCI to Bright, which closed on April 30, 2020, UCAP is a 100% owned subsidiary of APC and its 48.9% investment in UCI is an excluded asset that remains solely for the benefit of APC and its shareholders. As such, the gain on sale does not affect the net income and adjusted EBITDA attributes to ApolloMed.

⁽²⁾ Income from equity method investments is mainly attributed to the sale of UCAP's 48.9% investment in UCI to Bright, which closed on April 30, 2020. UCAP is a 100% owned subsidiary of APC and its 48.9% investment in UCI is an excluded asset that remains solely for the benefit of APC and its shareholders. As such, the gain on sale does not affect the net income and adjusted EBITDA attributable to ApolloMed.

O apollomed

www.apollomed.net

Use of Non-GAAP Financial Measures

This presentation contains the non-GAAP financial measures Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with GAAP is net (loss) income. These measures are not in accordance with, or are an alternative to, U.S. generally accepted accounting principles ("GAAP"), and may be different from other non-GAAP financial measures used by other companies. ApolloMed uses Adjusted EBITDA as a supplemental performance measure of its operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding losses from equity method investments provide bonus payments, impairment of intangibles, provision of doubtful accounts and other income earned that is not related to ApolloMed's normal operations. Adjusted EBITDA also excludes non recurring items, including the effect on EBITDA of certain recently acquired IPAs.

ApolloMed believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core and non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of ApolloMed's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators ApolloMed uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures is provided above.

Apollomed

www.apollomed.net

Key Acronyms

- ACO: Accountable Care Organization
- AIPBP: All-Inclusive Population-Based Payments
- APC: Allied Physicians of California IPA
- CMMI: Center for Medicare and Medicaid Innovation
- CMS: Centers for Medicare & Medicaid Services
- DME: Durable Medical Equipment
- Health Plan / Payors: Health Insurance Companies
- HMO: Health Maintenance Organization
- IPA: Independent Practice Association
- NCI: Non-Controlling Interest

- NMM: Network Medical Management
- MSA: Master Service Agreement
- MSO: Management Services Organization
- NGACO: Next Generation Accountable Care Organization
- PCP: Primary Care Physician
- PMPM: Per Member Per Month
- SNF: Skilled Nursing Facility
- VIE: Variable Interest Entity

S apollomed

www.apollomed.net

